23andMe Holding Co. (NASDAQ: ME) shares -were mostly unchanged Friday. The company, a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee.
One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances.
Homocysteine is an amino acid that plays a key role in important processes like making proteins. Vitamins B6, B12, and folate (also called B9) help convert homocysteine into other substances your body needs. This report is based on two common genetic variants in the MTHFR gene, called C677T and A1298C, that can lead to small increases in homocysteine levels. If homocysteine is too high, it can increase the risk of certain conditions such as cognitive decline and stroke.
This morning’s news release said, “most people with MTHFR variants are still expected to have homocysteine levels within the normal range. But for those who are concerned, a blood test can check homocysteine levels.”
The release went on to say, “Customers are able to order a lab test that is not readily available for most consumers from their doctors through 23andMe Labs to determine their levels and take action to lower them if needed.”
ME shares handed over a penny to $1.75 first thing Friday.
